In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Aarogya program aims to improve the overall health outcomes for the community by offering comprehensive health screenings, diagnostic support, and increased health awareness
Expect the international business including CDMO business to pick-up in the second half of the financial year
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Subscribe To Our Newsletter & Stay Updated
